Arcutis Biotherapeutics Director Howard G. Welgus plans to sell 10,000 common shares on 12/02/2024. The shares, acquired through a stock option exercise on 06/04/2018, have an aggregate market value of approximately $125,133.In the past 3 months, Welgus has sold 30,000 shares, generating total gross proceeds of $286,851. Previous sales include 10,000 shares each on 09/03/2024, 10/01/2024, and 11/01/2024, with gross proceeds of $107,695, $92,616, and $86,540 respectively.This transaction is part of a planned sale, with the plan adopted on 03/05/2024. Investors should note the ongoing divestment by the director, which may impact stock performance.

Arcutis Biotherapeutics Director Howard G. Welgus plans to sell 10,000 common shares on 12/02/2024. The shares, acquired through a stock option exercise on 06/04/2018, have an aggregate market value of approximately $125,133.In the past 3 months, Welgus has sold 30,000 shares, generating total gross proceeds of $286,851. Previous sales include 10,000 shares each on 09/03/2024, 10/01/2024, and 11/01/2024, with gross proceeds of $107,695, $92,616, and $86,540 respectively.This transaction is part of a planned sale, with the plan adopted on 03/05/2024. Investors should note the ongoing divestment by the director, which may impact stock performance.